Motol University Hospital

New International Study Reports Extension of the Donor Lung Transplantation Window

Retrieved on: 
화요일, 3월 12, 2024
FDA, Surgery, Medical Devices, Hospitals, Health, Clinic, Temperature, UZ Leuven, Transplant, Massachusetts General Hospital, Assistant, Motol University Hospital, Risk, Patient, Transport, Lung transplantation, Surgeon, Thorax, Ice, Dentistry

This milestone publication lays a strong foundation for future clinical applications in organ preservation and transplantation.

Key Points: 
  • This milestone publication lays a strong foundation for future clinical applications in organ preservation and transplantation.
  • For example, presenting a means to better accommodate longer transportation times, overnight bridging, or optimizing case scheduling during the day.
  • During the six-month study period, the LUNGguard® Donor Lung Preservation System was utilized to preserve donor lungs for over 15 hours in 13 separate instances.
  • Longer ischemic times increase the risk of primary graft dysfunction, a serious complication that can occur after lung transplantation.

T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference

Retrieved on: 
수요일, 4월 26, 2023
Hospice and palliative medicine, Fungemia, High, Motol University Hospital, Karolinska University Hospital, ECCMID, Patient, Fungal infection, Data, Blood, Poster, Blood culture, European Society of Clinical Microbiology and Infectious Diseases, Bloodstream infections, Infection, Medical imaging

LEXINGTON, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted new clinical data supporting the T2Bacteria® Panel and the T2Candida® Panel, that was recently presented at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Copenhagen, Denmark.

Key Points: 
  • LEXINGTON, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted new clinical data supporting the T2Bacteria® Panel and the T2Candida® Panel, that was recently presented at the European Society of Clinical Microbiology and Infectious Diseases (ECCMID) conference in Copenhagen, Denmark.
  • The data demonstrates the speed, accuracy and clinical benefits of the T2Dx® Instrument and T2 Biosystems’ sepsis panels.
  • Data presented at the Innovation Session analyzed the detection time of both T2Bacteria and T2 sepsis panels.
  • High Specificity and High Sensitivity: The T2 sepsis panels provided a tremendous improvement in the analytical phase of bloodstream infections detection.